menu search

ENTBF / Psychedelics Biotech Startup Launches Phase 1 Study On Ayahuasca's Active Ingredient

Psychedelics Biotech Startup Launches Phase 1 Study On Ayahuasca's Active Ingredient
Psychedelics biotech startup Entheon Biomedical ENBI ENTBF announced the approval by the local Dutch ethics committee for a Phase 1 clinical trial evaluating the pharmacokinetics, pharmacodynamics and safety profile of the psychedelic compound DMT. DMT is known as the active ingredient in ayahuasca, a ceremonial hallucinogenic concoction traditionally used by indigenous communities in some parts of South America. Read More
Posted: Feb 3 2022, 13:53
Author Name: Benzinga
Views: 111542

ENTBF News  

Psychedelics Biotech Startup Launches Phase 1 Study On Ayahuasca's Active Ingredient

By Benzinga
February 3, 2022

Psychedelics Biotech Startup Launches Phase 1 Study On Ayahuasca's Active Ingredient

Psychedelics biotech startup Entheon Biomedical ENBI ENTBF announced the approval by the local Dutch ethics committee for a Phase 1 clinical trial ev more_horizontal

Psychedelics Biotech Startup Launches Phase 1 Study On Ayahuasca's Active Ingredient

By Benzinga
February 3, 2022

Psychedelics Biotech Startup Launches Phase 1 Study On Ayahuasca's Active Ingredient

Psychedelics biotech startup Entheon Biomedical ENBI ENTBF announced the approval by the local Dutch ethics committee for a Phase 1 clinical trial ev more_horizontal

Psychedelics Biotech Startup Launches Phase 1 Study On Ayahuasca's Active Ingredient

By Benzinga
February 3, 2022

Psychedelics Biotech Startup Launches Phase 1 Study On Ayahuasca's Active Ingredient

Psychedelics biotech startup Entheon Biomedical ENBI ENTBF announced the approval by the local Dutch ethics committee for a Phase 1 clinical trial ev more_horizontal

Entheon Biomedical Acquires Lobo Genetics, Inc. in Bid to Strengthen Screening and Treatment Evaluation Tech for Psychedelics

By Benzinga
October 6, 2021

Entheon Biomedical Acquires Lobo Genetics, Inc. in Bid to Strengthen Screening and Treatment Evaluation Tech for Psychedelics

Image Provided by Wiki Commons Entheon Biomedical Corp. (OTCQB: ENTBF), the biotech research and development company focused on developing DMT-based t more_horizontal

Entheon Biomedical Acquires Lobo Genetics, Inc. in Bid to Strengthen Screening and Treatment Evaluation Tech for Psychedelics

By Benzinga
October 6, 2021

Entheon Biomedical Acquires Lobo Genetics, Inc. in Bid to Strengthen Screening and Treatment Evaluation Tech for Psychedelics

Image Provided by Wiki Commons Entheon Biomedical Corp. (OTCQB: ENTBF), the biotech research and development company focused on developing DMT-based t more_horizontal

Entheon Biomedical Acquires Lobo Genetics, Inc. in Bid to Strengthen Screening and Treatment Evaluation Tech for Psychedelics

By Benzinga
October 6, 2021

Entheon Biomedical Acquires Lobo Genetics, Inc. in Bid to Strengthen Screening and Treatment Evaluation Tech for Psychedelics

Image Provided by Wiki Commons Entheon Biomedical Corp. (OTCQB: ENTBF), the biotech research and development company focused on developing DMT-based t more_horizontal


Search within

Pages Search Results: